The breast invasive carcinoma (BRCA) patients were mainly categorized into four subtypes (Basal, Her2, LumA, and LumB) following the PAM50 classification, which exhibited a statistically significant difference in tumor immune response (P = 7.59 × 10-07, Kruskal-Wallis test, Figure 8A). This evidence concerns the gene TMEM43 and neoplasm.